Majority of cancer researchers have concentrated their efforts on tumor cells themselves to study tumor biology, morphology, and functions during tumor development and progression. However, tumor stromal variables, such as blood and lymph vessels, various stromal cells and proteins around tumor cells, have not drawn enough attention although they are at least equally important in tumor development, progression, and even tumor therapy. Tumor angiogenesis and lymphangiogenesis are the processes for formation of new blood or lymph vessels within and around tumor mass. Stromal cells consist of various cell types such as infiltrating immune cells, fibroblasts, and endothelial cells. Extracellular matrix (ECM) is a complex structural entity around the tumor cells, and often referred to connective tissue or ground substance. The ECM is composed of three major classes of structural proteins (collagen and elastin), specialized proteins (fibrillin, fibronectin and laminin) and pro-teoglycans (van den Hooff, 1988).
It is of importance to understand the role of stromal variables in tumor development and progression in order to design appropriate therapy against angiogenesis and other stromal proteinases. Based on the knowledge gained from this field, a number of anti-angiogenesis elements and matrix metalloproteinases (MMPs) inhibitors have been recently developed for clinical trials. Inactivation of stromal proteins inhibits angiogenesis, lymphangiogenesis, tumor growth, invasion, and metastasis. Consequently, this can stabilize and inhibit the tumor growth. In addition, stromal cells, compared to the tumor cells, are unlikely to develop drug resistance, although some stromal proteins are tumor-derived. In ger-enal, most of the stromal proteins are the products of stromal cells. One of the problems with traditional chemotherapy and radiotherapy is that they indiscriminately affect both growing normal and tumor tissue. Therefore, a therapy targeted to the stromal will minimize the side-effects of anti-cancer therapy. Several characteristics of stromal variables make them to be attractive therapeutic targets.
In this chapter, we focus on clinicopathological aspects of tumor stromal variables, such as angiogenesis, lymphangiogenesis, inflammatory infiltration, and particularly interesting new cysteine-histidine rich proteins (PINCH) and stromelysin-3 (ST3) in colorectal cancer (CRC).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Acikalin, M.F., Oner, U., Topcu, I., Yasar, B., Kiper, H., and Colak, E. 2005. Tumour angiogenesis and mast cell density in the prognostic assessment of colorec-tal carcinomas. Dig. Liver Dis. 37: 162–169.
Akagi, K., Ikeda, Y., Miyazaki, M., Abe, T., Kinoshita, J., Maehara, Y., and Sugimachi, K. 2000. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br. J. Cancer 83: 887–891.
Basset, P., Bellocq, J.P., Wolf, C., Stoll, I., Hutin, P., Limacher, J.M., Podhajcer, O.L., Chenard, M.P., Rio, M.C., and Chambon, P. 1990. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348: 699–704.
Björndahl, M. 2005. Lymphanginogenesis and lymphatic metastasis. Thesis; ISBN: 91-7140-562-3.
Bossi, P., Viale, G., Lee, A.K., Alfano, R., Coggi, G., and Bosari, S. 1995. Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res. 55: 5049–5053.
Boulay, A., Masson, R., Chenard, M.P., El.Fahime, M., Cassard, L., Bellocq, J.P., Sautes-Fridman, C., Basset, P., and Rio, MC. 2001. High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix met-alloproteinase. Cancer Res. 61: 2189–2193.
Burridge, K., and Chrzanowska-Wodnicka, M. 1996. Focal adhesions, contractility, and signaling. Annu. Rev. Cell Dev. Biol. 12: 463–518.
Cascinu, S., Staccioli, M.P., Gasparini, G., Giordani, P., Catalano, V., Ghiselli, R., Rossi, C., Baldelli, A.M., Graziano, F., Saba, V., Muretto, P., and Catalano, G. 2000. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin. Cancer Res. 6: 2803–2807.
Choi, H.J., Hyun, M.S., Jung, G.J., Kim, S.S., and Hong, S.H. 1998. Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology 55: 575–581.
Dimitriadou, V., and Koutsilieris, M. 1997. Mast cell-tumor cell interactions: for or against tumour growth and metastasis? Anticancer Res. 17: 1541–1549.
Dundas, S.A., Laing, R.W., O'Cathain, A., Seddon, I., Slater, D.N., Stephenson, T.J., and Underwood, J.C. 1988. Feasibility of new prognostic classification for rectal cancer. J. Clin. Pathol. 41: 1273–1276.
Egeblad, M., and Werb, Z. 2002. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2: 161–174.
Fogt, F., Zimmerman, R.L., Ross, H.M., Daly, T., and Gausas, R.E. 2004. Identification of lymphatic vessels in malignant, adenomatous and normal colonic mucosa using the novel immunostain D2–40. Oncol. Rep. 11: 47–50.
Fossum, B., Gedde-Dahl, T. 3rd., Breivik, J., Eriksen, J.A., Spurkland, A., Thorsby, E., and Gaudernack, G. 1994. p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4 + and CD8 + T cells recognize a peptide corresponding to a common mutation (13Gly— > Asp). Int. J. Cancer 56: 40–45.
Fox, S.H., Whalen, G.F., Sanders, M.M., Burleson, J.A., Jennings, K., Kurtzman, S., and Kreutzer, D. 1998. Angiogenesis in normal tissue adjacent to colon cancer. J. Surg. Oncol. 69: 230–234.
Fujita, S., Shimoda, T., Yoshimura, K., Yamamoto, S., Akasu, T., and Moriya, Y. 2003. Prospective evaluation of prognostic factors in patients with colorectal cancer undergoing curative resection. J. Surg. Oncol. 84: 127–131.
Gao, J., Arbman, G., Rearden, A., and Sun, X.F. 2004. Stromal staining for PINCH is an independent prognostic indicator in colorectal cancer. Neoplasia 6: 796–801.
Gao, J., Arbman, G., Wadhra, T.I., Zhang, H., and Sun, X.F. 2005. Relationships of tumor inflammatory infiltration and necrosis with microsatel-lite instability in colorectal cancers. World. J. Gastroenterol. 11: 2179–2183.
Guo, L., and Wu, C. 2002. Regulation of fibronectin matrix deposition and cell proliferation by the PINCH-ILK-CH-ILKBP complex. FASEB. J. 16: 1298–1300.
Hanrahan, V., Currie, M.J., Gunningham, S.P., Morrin, H.R., Scott, P.A., Robinson, B.A., and Fox, S.B. 2003. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J. Pathol. 200: 183–194.
Kaattari, S., Scibienski, R.J, and Benjamini, E. 1980. The immunoregulatory role of antigen-antibody complexes. I. Assessment of B and T-cell responses. Immunology 40: 9–16.
Khorana, A.A., Ryan, C.K., Cox, C., Eberly, S., and Sahasrabudhe, D.M. 2003. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer 97: 960–968.
Knutsen, A., Adell, G., and Sun, X.F. 2006. Inflammatory infiltration, fibrosis, necrosis and mucinous content in relation to clinicopathological and molecular factors in rectal cancers with or without preoperative radiotherapy. Oncol. Rep. 16: 231–237.
Koukourakis, M.I., Giatromanolaki, A., Sivridis, E., Gatter, K.C., and Harris, A.L. 2005. Tumour and Angiogenesis Research Group. Tumour and Angiogenesis Research Group. Inclusion of vasculature-related variables in the Dukes staging system of colon cancer. Clin. Cancer Res. 11: 8653–8660.
Kuramochi, H., Hayashi, K., Uchida, K., Miyakura, S., Shimizu, D., Vallbohmer, D., Park, S., Danenberg, K.D., Takasaki, K., and Danenberg, P.V. 2006. Vascular endothelial growth factor messenger rna expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin. Cancer Res. 12: 29–33.
Kuroyama, S., Kobayashi, N., Ohbu, M., Ohtani, Y., Okayasu, I., and Kakita, A. 2005. Enzyme histochemical analysis of lymphatic vessels in colon carcinoma: occurrence of lymphangiogen-esis within the tumor. Hepatogastroenterology 52: 1057–1061.
Li, C., Gardy, R., Seon, B.K., Duff, S.E., Abdalla, S., Renehan, A., O'Dwyer, S.T., Haboubi, N., and Kumar, S. 2003. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br. J. Cancer 88: 1424–1431.
Manes, S., Mira, E., Barbacid, M.M., Cipres, A., Fernandez-Resa, P., Buesa, J.M., Merida, I., Aracil, M., Marquez, G., and Martinez-A, C. 1997. Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human strome-lysin-3. J. Biol. Chem. 272: 25706–25712.
Menon, A.G., Janssen-van Rhijn, C.M., Morreau, H., Putter, H., Tollenaar, R.A., van de Velde, C.J., Fleuren, G.J., and Kuppen, P.J. 2004. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab. Invest. 84: 493–501.
Onogawa, S., Tanaka, S., Oka, S., Morihara, M., Kitadai, Y., Sumii, M., Yoshihara, M., Shimamoto, F., Haruma, K., and Chayama, K. 2002. Clinical significance of angiogenesis in rectal carcinoid tumors. Oncol. Rep. 9: 489–494.
O'Reilly, M.S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R.A., Moses, M., Lane, W.S., Cao, Y., Sage, E.H., and Folkman, J. 1994. Angiostatin: a novel angiogenesis inhibitor that mediates the uppression of metastases by a Lewis lung carcinoma. Cell 79: 315–328.
Porte, H., Chastre, E., Prevot, S., Nordlinger, B., Empereur, S., Basset, P., Chambon, P., and Gespach, C. 1995. Neoplastic progression of human colorectal cancer is associated with over expression of the stromelysin-3 and BM-40/SPARC genes. Int. J. Cancer 64: 70–75.
Rearden, A. 1994. A new LIM protein containing an autoepitope homologous to “senescent cell antigen”. Biochem. Biophys. Res. Commun. 201: 1124–1131.
Shan, Y.S., Lee, J.C., Chow, N.H., Yang, H.B., and Wang, S.T. 2003. Immunohistochemical micro-vessel count is not a reliable prognostic predictor in colorectal carcinoma. Hepatogastroenterology 50: 1316–1320.
Sharma, R.A., Dalgleish, A.G., Steward, W.P., and O'Byrne, K.J. 2003. Angiogenesis and the immune response as targets for the prevention and treatment of colorectal cancer. Oncol. Rep. 10: 1625–1631.
Sivridis, E., Giatromanolaki, A., and Koukourakis, M.I. 2004. “Stromatogenesis” and tumor progression. Int. J. Surg. Pathol. 12: 1–9.
Skobe, M., Hawighorst, T., Jackson, D.G., Prevo, R., Janes, L., Velasco, P., Riccardi, L., Alitalo, K., Claffey, K., and Detmar, M. 2001. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7: 192–198.
Skoglund, J., Emterling, A., Arbman, G., Anglard, P., and Sun, X.F. 2004. Clinicopathological significance of stromelysin-3 expression in colorectal cancer. Oncology 67: 67–72.
Stacker, S.A., Caesar, C., Baldwin, M.E., Thornton, G.E., Williams, R.A., Prevo, R., Jackson, D.G., Nishikawa, S., Kubo, H., and Achen, M.G. 2001. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7: 186–191.
Sun, Y., Cheung, J.M., Martel-Pelletier, J., Pelletier, J.P., Wenger, L., Altman, R.D., Howell, D.S., and Cheung, H.S. 2000. Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13). J. Biol. Chem. 275: 11327–11332.
Sun, X, F., and Zhang, H. 2006. Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP, and PINCH in Colorectal carcinomas. Mol. Cancer 5: 43–63
Thewes, M., Pohlmann, G., Atkinson, M., Mueller, J., Putz, B., and Hofler, H. 1996. Stromelysin-3 (ST3) mRNA expression in colorectal carcinomas. Diagn. Mol. Pathol. 5: 284–290.
van den Hooff, A. 1988. Stromal involvement in malignant growth. Adv. Cancer Res. 50: 159–196.
Varani, J. 1987. Interaction of tumor cells with the extracellular matrix. Revis. Biol. Celular. 12: 1–113.
Vermeulen, P.B., Van den Eynden, G.G., Huget, P., Goovaerts, G., Weyler, J., Lardon, F., Van Marck, E., Hubens, G., and Dirix, L.Y. 1999. Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br. J. Cancer 79: 316–322.
Wallin, Å., Svanvik, J., Adell, G., and Sun, X.F. 2006. Expression of PRL proteins at the margin of rectal cancers in relation to preoperative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 65: 452–458.
Wang, T.B., Huang, Y.H., Lan, P., Song, X.M., and Wang, J.P. 2005. Correlation of lymphang-iogenesis to progression of colorectal cancer. Ai Zheng 24: 1276–1279.
White, J.D., Hewett, P.W., Kosuge, D., McCulloch, T., Enholm, B.C., Carmichael, J., and Murray, J.C. 2002. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res. 62: 1669–1675.
Wlodarczyk, J., Bethke, B., Mueller, E., Stolte, M., and Mueller, J. 2001. A comparative study of E-cadherin and stromelysin-3 expression in de novo and ex adenoma carcinoma of the colorec-tum. Virchows Arch. 439: 756–761.
Zhang, Y., Chen, K., Tu, Y., and Wu, C. 2004. Distinct roles of two structurally closely related focal adhesion proteins, alpha-parvins and beta-parvins, in regulation of cell morphology and survival. J. Biol. Chem. 279: 41695–41705.
Zhao, Z.R., Zhang, Z.Y., Cui, D.S., Jiang, L,. Zhang, H.J., Wang, M.W., and Sun, X.F. 2006. PINCH expression in colorectal adenocarci-noma. World J. Gastroenterol. 12: 298–301.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science + Business Media B.V.
About this chapter
Cite this chapter
Sun, XF., Zhang, H. (2009). Role of Stromal Variables in Development and Progression of Colorectal Cancer. In: Hayat, M.A. (eds) Colorectal Cancer. Methods of Cancer Diagnosis, Therapy, and Prognosis, vol 4. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-9545-0_11
Download citation
DOI: https://doi.org/10.1007/978-1-4020-9545-0_11
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-9544-3
Online ISBN: 978-1-4020-9545-0
eBook Packages: MedicineMedicine (R0)